Previous 10 | Next 10 |
Motif Bio (NASDAQ: MTFB ) -75% on receiving CRL from FDA. More news on: Motif Bio, Inovio Pharmaceuticals, Inc., Sierra Wireless, Inc., Stocks on the move, Read more ...
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration ...
Noteworthy events during the week of February 10 - 16 for healthcare investors. More news on: Momenta Pharmaceuticals, Inc., Motif Bio, AVEO Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will participate in the following event: Jefferies London Healthcare Conference Nove...
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at two upcoming scientific conferences. IDWeek 2018 October 3-7,...
SOMERVILLE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the appointment of Robert Dickey IV as Managing Di...
Iclaprim overview presented in State of the Art Lecture Safety analysis of diabetic patients in REVIVE ABSSSI trials shows fewer adverse events versus vancomycin Surveillance data confirm in vitro activity of iclaprim against wide variety of Gram-positive bacteria, including drug-resi...
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at the upcoming European Society of Clinical Microbiology and Infectiou...
Stocks in News: MTFB, MDXG FDA accepts Motif Bio's NDA with priority review for Iclaprim Discussion : FDA accepted for filing the NDA of Motif Bio’s ( MTFB ) iclaprim. Iclaprim is a gram-positive investigational antibiotic, targeted for the treatment of acute bacterial skin and...
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AVEO partner moves forward with a HER3 treatment in China Company: CANbridge Life Scien...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company") announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares (ADSs)...
NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will be utilising NIAID’s 1 suite of preclinical services through JMI Laboratories ...
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its Lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreemen...